Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COARTEM vs QUIOFIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Artemether and lumefantrine are antimalarial agents that act as blood schizonticides. Artemether is rapidly metabolized to dihydroartemisinin, which generates free radicals that damage parasite proteins and membranes. Lumefantrine inhibits the formation of beta-hematin (hemozoin) by forming a complex with hemin, thereby preventing parasite detoxification of heme.
QUIOFIC (difelikefalin) is a selective agonist of the kappa-opioid receptor (KOR). Activation of KOR on peripheral sensory neurons and immune cells inhibits the release of pro-inflammatory mediators and reduces pruritus signaling, particularly in chronic kidney disease-associated pruritus.
Treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum,Treatment of uncomplicated malaria due to Plasmodium vivax (in combination with primaquine for radical cure)
FDA-approved: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis,Off-label: Not established
4 tablets (each containing artemether 20 mg and lumefantrine 120 mg) orally twice daily for 3 days (total of 6 doses). Doses should be taken with fatty food to enhance absorption. Repeat dosing if vomiting occurs within 1 hour after administration.
Quiofic (diroximel fumarate) 462 mg orally twice daily.
Artemether: terminal elimination half-life ~1–3 hours (rapid, consistent with its role in rapid parasite clearance). Lumefantrine: terminal elimination half-life ~4–6 days (mean 4.5 days in healthy volunteers; longer in malaria patients due to increased Vd and protein binding). The prolonged half-life of lumefantrine ensures effective post-treatment prophylaxis.
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged to 30-50 hours in severe renal impairment (Cr Cl <30 m L/min).
Artemether is metabolized primarily by CYP3A4 and CYP3A5 to dihydroartemisinin. Lumefantrine is metabolized by CYP3A4.
Metabolized primarily via enzymatic hydrolysis by carboxylesterase 1 (CES1); minor contribution from CYP3A4. Approximately 7% excreted unchanged in urine.
Artemether is primarily metabolized in the liver via CYP3A4; its metabolites are excreted in feces (approximately 80%) and urine (minor). Lumefantrine is also hepatically metabolized (CYP3A4) and excreted predominantly in feces (90%) with minimal renal excretion (<1%). Overall, both drugs are eliminated mainly via biliary/fecal routes. Renal excretion is negligible.
Primarily renal as unchanged drug (60-70%) and as active metabolite (10-15%); biliary/fecal excretion accounts for 15-20%.
Artemether: >95% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Lumefantrine: >99% bound to plasma proteins (mainly albumin and α1-acid glycoprotein).
70-80% bound to serum albumin.
Artemether: Vd ~2–4 L/kg (large, indicating extensive tissue distribution). Lumefantrine: Vd ~10–20 L/kg (very large, suggesting deep tissue compartment, likely due to high lipophilicity and protein binding).
4-6 L/kg; indicates extensive tissue distribution (e.g., lungs, kidneys, liver).
Oral bioavailability of Coartem fixed-dose combination: artemether ~40% (with food) but highly variable; absorption is enhanced by fat. Lumefantrine oral bioavailability is highly variable (approximately 20–50%) and significantly increased when taken with food (especially fatty meals). Coartem should be taken with food to maximize absorption.
Oral: 85-92%.
No dose adjustment required for mild to moderate renal impairment. Safety and efficacy not established in severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
No dosage adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (Cr Cl <30 m L/min).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Contraindicated in severe hepatic impairment (Child-Pugh class C).
No formal studies in hepatic impairment. Use with caution in severe hepatic impairment (Child-Pugh C).
Weight-based dosing: 5-15 kg: 1 tablet per dose; 15-25 kg: 2 tablets per dose; 25-35 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose. Administer orally twice daily for 3 days (total of 6 doses) with fatty food.
Safety and efficacy not established in pediatric patients under 18 years.
No specific dose adjustment required; follow adult dosing. Caution in elderly due to potential for QT prolongation and concurrent medications. Monitor for cardiac effects.
No specific dose adjustment; use with consideration of renal function due to age-related decline.
None.
None.
QT interval prolongation: caution in patients with risk factors for QT prolongation, electrolyte abnormalities, or concomitant use of drugs that prolong QT interval.,Parasite resistance: monitor for clinical failure.,Re-evaluate if severe malaria develops.,Use with caution in patients with hepatic or renal impairment.,Potential for drug interactions with CYP3A4 inducers/inhibitors.
May cause dizziness, somnolence, or gait disturbances; avoid driving or operating heavy machinery until effects are known. Risk of falls, particularly in elderly patients. Hypotension has been reported. Use with caution in patients with hepatic impairment.
Hypersensitivity to artemether, lumefantrine, or any component of the formulation.,Concomitant therapy with drugs that are metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, metoprolol, imipramine, amitriptyline, clomipramine) due to potential QT prolongation.,Severe malaria (parenteral therapy recommended).
None known.
Take with fatty food (e.g., whole milk, cheese, or a meal containing fat) to increase absorption, especially of lumefantrine. Avoid grapefruit juice. Alcohol may increase risk of hepatotoxicity and should be avoided.
No significant food interactions. Administer after meals to optimize drug contact with intestinal parasites. Avoid alcohol as it may exacerbate GI side effects.
Pregnancy Category C. First trimester: Avoid; teratogenic effects observed in animal studies (skeletal malformations) at clinically relevant doses. Second and third trimesters: Data limited; use only if benefit outweighs risk. Malaria infection poses higher fetal risk than treatment.
QUIOFIC (quinupristin/dalfopristin) is pregnancy category B. Animal studies have not demonstrated teratogenic effects; however, no adequate and well-controlled studies exist in pregnant women. Human fetal risk during the first trimester is considered low, but caution is advised. In the second and third trimesters, use only if clearly needed, as systemic infections may pose maternal-fetal risk. There is no evidence of congenital malformations associated with quinupristin/dalfopristin.
Artemether and lumefantrine are excreted into breast milk in low amounts. M/P ratio not determined. Based on limited data, the American Academy of Pediatrics considers it compatible with breastfeeding. Monitor infant for potential adverse effects (diarrhea, vomiting).
Quinupristin/dalfopristin is excreted into human breast milk in low concentrations. The milk-to-plasma ratio (M/P) is not precisely defined; based on limited data, it is estimated to be <0.5. Due to potential for gastrointestinal disturbance and allergic reactions in the nursing infant, caution is recommended. Consider the benefits of breastfeeding and the importance of the drug to the mother. Alternatives with better safety data may be preferred.
No routine dose adjustment required in pregnancy. Pharmacokinetic studies show no clinically significant changes in artemether or lumefantrine exposure during pregnancy compared to non-pregnant adults. Administer standard weight-based dosing.
Pregnancy-induced physiological changes may alter the pharmacokinetics of quinupristin/dalfopristin, though specific dosing adjustments are not established. Increased volume of distribution and enhanced renal clearance in pregnancy may reduce drug exposure. Based on limited data, no dosage adjustment is recommended, but careful monitoring of clinical response is warranted. In cases of severe infections, consider therapeutic drug monitoring if available.
Coartem (artemether/lumefantrine) is a first-line treatment for uncomplicated Plasmodium falciparum malaria. Administer with fatty food to enhance absorption (especially lumefantrine). Monitor for QT prolongation, especially in patients with electrolyte abnormalities, bradycardia, or concurrent use of QT-prolonging drugs. Do not use for severe malaria or as prophylaxis. Not recommended in children <5 kg. Repeat dose if vomiting occurs within 1 hour of administration.
QUIOFIC (quinfamide) is an intraluminal amebicide used for intestinal amebiasis. It is not absorbed systemically, thus has no effect on extraintestinal amebiasis. Administer after meals to ensure drug contact with parasites in the intestinal lumen. Monitor for GI upset; hepatotoxicity is rare. Avoid in patients with known hypersensitivity to dichloroacetamide derivatives.
Take Coartem with a full meal or fatty food (e.g., milk, cheese) to help the medicine work better.,Complete the full course of 6 doses over 3 days even if you feel better.,If you vomit within 1 hour after taking a dose, take another dose with food.,Avoid grapefruit juice during treatment as it may affect the medication.,Report any signs of irregular heartbeat, dizziness, or fainting immediately.,Use effective birth control during treatment and for 1 month after the last dose, as Coartem may reduce hormonal contraceptive effectiveness.,Not to be used for prevention of malaria.,Keep out of reach of children.
Take this medication exactly as prescribed, usually after meals to maximize its effect on intestinal amebae.,Complete the full course of therapy even if you feel better to ensure eradication of the infection.,Report any signs of liver problems such as jaundice, dark urine, or abdominal pain immediately.,This drug is not effective for infections outside the intestines; additional medications may be needed for liver amebiasis.,Common side effects include nausea, vomiting, and diarrhea; if severe, contact your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COARTEM vs QUIOFIC, answered by our medical review team.
COARTEM is a Antimalarial Agent that works by Artemether and lumefantrine are antimalarial agents that act as blood schizonticides. Artemether is rapidly metabolized to dihydroartemisinin, which generates free radicals that damage parasite proteins and membranes. Lumefantrine inhibits the formation of beta-hematin (hemozoin) by forming a complex with hemin, thereby preventing parasite detoxification of heme.. QUIOFIC is a Antimalarial Agent that works by QUIOFIC (difelikefalin) is a selective agonist of the kappa-opioid receptor (KOR). Activation of KOR on peripheral sensory neurons and immune cells inhibits the release of pro-inflammatory mediators and reduces pruritus signaling, particularly in chronic kidney disease-associated pruritus.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COARTEM and QUIOFIC depend on the specific clinical indication. These are both Antimalarial Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COARTEM is: 4 tablets (each containing artemether 20 mg and lumefantrine 120 mg) orally twice daily for 3 days (total of 6 doses). Doses should be taken with fatty food to enhance absorption. Repeat dosing if vomiting occurs within 1 hour after administration.. The standard adult dose of QUIOFIC is: Quiofic (diroximel fumarate) 462 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COARTEM and QUIOFIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COARTEM is classified as Category C. Pregnancy Category C. First trimester: Avoid; teratogenic effects observed in animal studies (skeletal malformations) at clinically relevant doses. Second and third trimesters: Dat. QUIOFIC is classified as Category C. QUIOFIC (quinupristin/dalfopristin) is pregnancy category B. Animal studies have not demonstrated teratogenic effects; however, no adequate and well-controlled studies exist in pre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.